Insider · CIK 0001816196
Michel Detheux
ceoofficerdirector
Files at ITOS (iTeos Therapeutics, Inc.), VOR (Vor Biopharma Inc.). First filing Jun 6, 2025, latest Jun 11, 2025.
In brief
Michel Detheux files SEC Form 4 as CEO and director at ITOS (iTeos Therapeutics, Inc.), and also at VOR (Vor Biopharma Inc.). Since Jun 6, 2025, Michel Detheux has reported 0 open-market buys worth $0 and 2 open-market sells worth $2.6M, the latest filed on Jun 11, 2025.
A track record needs three past buys with six months of prices behind them; Michel Detheux has 0, so none is measured yet.
The newest scored trade: sold $1.0M of ITOS on Jun 9, 2025, filed Jun 11, 2025, scored 43 (moderate), under a 10b5-1 plan.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $2.6M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | iTeos Therapeutics, Inc. | $1.0M 104,565 shares | -72% | - | |
| 43Moderate | iTeos Therapeutics, Inc. | $1.6M 156,847 shares | -109% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | 52,283 0.14% of outstanding | $524k | Jun 10, 2025 | $2.1M |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | 52,282 0.14% of outstanding | $532k | Jun 9, 2025 | $1.6M |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | 52,282 0.14% of outstanding | $533k | Jun 6, 2025 | $1.1M |
| Jun 5, 2025 | ITOS iTeos Therapeutics, Inc. | 52,282 0.14% of outstanding | $534k | Jun 5, 2025 | $528k |
| Jun 4, 2025 | ITOS iTeos Therapeutics, Inc. | 52,283 0.14% of outstanding | $526k | Jun 4, 2025 | none |
Transactions
Every row this insider has filed, 48 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | VOR Vor Biopharma Inc. | AGrant or award Stock option (right to buy)derivative | +57,162 | $0.00 | $0 | 57,162 | Jun 12, 2026 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | UTender of shares Common Stock | -153,903 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | UTender of shares Common Stockindirect: By MG3A | -94,027 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,185 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -444,815 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -94,336 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,128 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,544 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By MG3A | -185,000 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By MG3A | -52,700 | - | - | 0 | Aug 29, 2025 |
| Jul 16, 2025 | VOR Vor Biopharma Inc. | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jul 18, 2025 |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 11, 2025 |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.03 | $84k | 135,903 | Jun 11, 2025 |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,882 | $4.30 | $189k | 43,882 | Jun 11, 2025 |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,882 | $10.03 | $440k | 0 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.02 | $84k | 135,903 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,883 | $4.30 | $189k | 43,883 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,883 | $10.02 | $440k | 0 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +18,000 | $4.30 | $77k | 153,903 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stockindirect: By MG3A10b5-1 | +94,027 | $4.30 | $404k | 94,027 | Jun 11, 2025 |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 26,400 | Jun 11, 2025 |
| Jun 9, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,882 | $0.00 | $0 | 137,913 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 18,000 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,883 | $0.00 | $0 | 94,030 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,000 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Jun 10, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -94,027 | $0.00 | $0 | 3 | Jun 11, 2025 |
| Jun 4, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 6, 2025 |
| Jun 4, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.10 | $85k | 135,903 | Jun 6, 2025 |
| Jun 4, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,883 | $4.30 | $189k | 43,883 | Jun 6, 2025 |
| Jun 4, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,883 | $10.10 | $443k | 0 | Jun 6, 2025 |
| Jun 5, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 6, 2025 |
| Jun 5, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.15 | $85k | 135,903 | Jun 6, 2025 |
| Jun 5, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,882 | $4.30 | $189k | 43,882 | Jun 6, 2025 |
| Jun 5, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,882 | $10.15 | $445k | 0 | Jun 6, 2025 |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 6, 2025 |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.21 | $86k | 135,903 | Jun 6, 2025 |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,882 | $4.30 | $189k | 43,882 | Jun 6, 2025 |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,882 | $10.21 | $448k | 0 | Jun 6, 2025 |
| Jun 4, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 51,600 | Jun 6, 2025 |
| Jun 4, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,883 | $0.00 | $0 | 269,559 | Jun 6, 2025 |
| Jun 5, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 43,200 | Jun 6, 2025 |
| Jun 5, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,882 | $0.00 | $0 | 225,677 | Jun 6, 2025 |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 34,800 | Jun 6, 2025 |
| Jun 6, 2025 | ITOS iTeos Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,882 | $0.00 | $0 | 181,795 | Jun 6, 2025 |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | AGrant or award Common Stock | +77,000 | $0.00 | $0 | 135,903 | Mar 11, 2025 |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +459,000 | $0.00 | $0 | 459,000 | Mar 11, 2025 |
| Dec 5, 2023 | ITOS iTeos Therapeutics, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 58,903 | Dec 7, 2023 |
Questions about Michel Detheux
Answered from the filings on this page, as of the latest one.
Is Michel Detheux buying or selling?
Not in the last 12 months. Michel Detheux's latest open-market trade on SEC Form 4 was sold $1.0M of ITOS on Jun 9, 2025.
How did Michel Detheux's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michel Detheux has 0.
Where does Michel Detheux file Form 4?
Michel Detheux has filed Form 4 at ITOS (iTeos Therapeutics, Inc.) as Chief Executive Officer; VOR (Vor Biopharma Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.